<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>tumor evolution tracking &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/tumor-evolution-tracking/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 15 Oct 2025 16:39:47 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>tumor evolution tracking &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>High-Speed Whole-Body SPECT Technology Advances Tracking of Tumor Evolution to Enhance Prostate Cancer Treatment</title>
		<link>https://bioengineer.org/high-speed-whole-body-spect-technology-advances-tracking-of-tumor-evolution-to-enhance-prostate-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 15 Oct 2025 16:39:31 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[**Tags:** High-Speed SPECT imaging]]></category>
		<category><![CDATA[177Lu-PSMA therapy]]></category>
		<category><![CDATA[prostate cancer treatment]]></category>
		<category><![CDATA[tumor evolution tracking]]></category>
		<guid isPermaLink="false">https://bioengineer.org/high-speed-whole-body-spect-technology-advances-tracking-of-tumor-evolution-to-enhance-prostate-cancer-treatment/</guid>

					<description><![CDATA[image: Figure 2: Maximum-intensity projection images from [68Ga]Ga-PSMA and [18F]-FDG PET before treatment, and [177Lu]Lu SPECT displayed without and with (red) segmentation with SUV of >3 in 74-y-old mCRPC patient. [177Lu]Lu-PSMA therapy was stopped at third injection despite dramatic decrease in PSA because of lack of favorable impact on symptoms and worsening clinical condition, and patient died 6 months [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">281545</post-id>	</item>
		<item>
		<title>Tracking Tumor DNA During Gastric Cancer Treatment</title>
		<link>https://bioengineer.org/tracking-tumor-dna-during-gastric-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 01 Aug 2025 20:42:08 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[ctDNA monitoring]]></category>
		<category><![CDATA[gastric cancer biomarkers]]></category>
		<category><![CDATA[Liquid biopsy applications]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[tumor evolution tracking]]></category>
		<guid isPermaLink="false">https://bioengineer.org/tracking-tumor-dna-during-gastric-cancer-treatment/</guid>

					<description><![CDATA[In the rapidly evolving field of oncology, the pursuit of non-invasive biomarkers that can dynamically track tumor evolution during treatment is a paramount goal, especially for aggressive cancers where early intervention can dramatically shift the prognosis. Recent advances have pointed to circulating tumor DNA (ctDNA) as a promising candidate, a molecular beacon shed into the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">252531</post-id>	</item>
	</channel>
</rss>
